Since RASSF5 and other RASSF family members are inactivated by promoter hypermethylation in numerous cancer cell lines and primary cancers (32, 33), reintroduction of small proteins derived from such effectors with enhanced Ras affinity is an attractive strategy against cancer. This evidence concerns the gene RASSF5 and cancer.